DCM
REGN icon

Davis Capital Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Davis Capital Management’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.25K Buy
2
+1
+100% +$681 ﹤0.01% 455
2026
Q1 		$773 Hold
1
– – ﹤0.01% 362
2025
Q4 		$772 Hold
1
– – ﹤0.01% 354
2025
Q3 		$562 Buy
+1
New +$565 ﹤0.01% 392

Other funds holding REGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Davis Capital Management's REGN Position: Q2 2026 in Review

Davis Capital Management increased its Regeneron Pharmaceuticals (REGN) stake by 100% in Q2 2026, buying an estimated $681 and bringing the position to 2 shares worth $1.25K. The position accounts for ﹤0.01% of the portfolio, ranked #455.

Davis Capital Management first reported a position in REGN in Q3 2025 and has held it in 4 quarters since. 1,332 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • Davis Capital Management held 2 shares of Regeneron Pharmaceuticals worth $1.25K as of Q2 2026.
  • Davis Capital Management bought 1 Regeneron Pharmaceuticals share in Q2 2026, an estimated $681.
  • Regeneron Pharmaceuticals made up ﹤0.01% of Davis Capital Management's portfolio in Q2 2026, its #455 holding.
  • Davis Capital Management first reported a position in Regeneron Pharmaceuticals in Q3 2025 and has held it in 4 quarters since.
  • 1,332 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Davis Capital Management's 13F filing for Q2 2026, filed 16 Jul 2026.